Atrion Corporation

NasdaqGS:ATRI 주식 리포트

시가총액: US$809.4m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Atrion 향후 성장

Future 기준 점검 0/6

현재 Atrion 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

핵심 정보

n/a

이익 성장률

n/a

EPS 성장률

Medical Equipment 이익 성장16.1%
매출 성장률n/a
향후 자기자본이익률n/a
애널리스트 커버리지

None

마지막 업데이트n/a

최근 향후 성장 업데이트

Recent updates

분석 기사 • May 22

There May Be Some Bright Spots In Atrion's (NASDAQ:ATRI) Earnings

Soft earnings didn't appear to concern Atrion Corporation's ( NASDAQ:ATRI ) shareholders over the last week. We did...
Seeking Alpha • Mar 24

Atrion Corporation Is Overvalued For The Direction Fundamentals Are Heading

Summary Atrion Corporation, a healthcare company focused on fluid delivery products, has experienced a decline in revenue, profits, and cash flows. The drop in sales of fluid delivery products, which account for 42% of overall revenue, has severely impacted the company's top line. Despite the potential for improvement in the future, the stock is currently expensive compared to similar companies, warranting a cautious outlook and a downgrade to a 'sell' rating. Read the full article on Seeking Alpha
분석 기사 • Mar 23

Subdued Growth No Barrier To Atrion Corporation (NASDAQ:ATRI) With Shares Advancing 25%

Atrion Corporation ( NASDAQ:ATRI ) shareholders would be excited to see that the share price has had a great month...
분석 기사 • Feb 09

Here's Why Atrion (NASDAQ:ATRI) Can Manage Its Debt Responsibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
분석 기사 • Jan 04

Atrion Corporation's (NASDAQ:ATRI) 26% Share Price Surge Not Quite Adding Up

Those holding Atrion Corporation ( NASDAQ:ATRI ) shares would be relieved that the share price has rebounded 26% in the...
분석 기사 • Sep 14

Atrion (NASDAQ:ATRI) Seems To Use Debt Quite Sensibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
분석 기사 • Jul 18

Atrion (NASDAQ:ATRI) Will Want To Turn Around Its Return Trends

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...
분석 기사 • Apr 19

Be Wary Of Atrion (NASDAQ:ATRI) And Its Returns On Capital

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
분석 기사 • Oct 18

Atrion (NASDAQ:ATRI) May Have Issues Allocating Its Capital

There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...
Seeking Alpha • Sep 08

Atrion: Attractively Priced For Exposure To Defensive Healthcare

Summary Artrion Corp. looks well positioned to continue delivering stable, predictable future cash flows. The stock is ideal for those seeking defensive characteristics into equity portfolios. Shares look attractively priced by our estimate of fair value. We rate ATRI a buy on a $632 valuation. Investment Summary Defensive healthcare looks well positioned to catch a bid in the current investment landscape as investors turn to factors of quality and resiliency. Earnings quality and fundamental momentum are paramount to overcome the deep drawdowns experienced across equity markets in FY22. With that, we look to Atrion Corporation (ATRI), a low volatility offering with extensive business history and deep customer networks. ATRI is ideal for investors seeking to add a defensive overlay to equity portfolios, and shares look attractively priced by our estimation. There's also the $2.15 recently declared dividend [+10.3% YoY] that is not discussed here. We rate ATRI a buy $632 price target. Atrion Q2 earnings: in-line with mature growth cycle ATRI came in with a strong set of numbers once again, with top-line growth of 14% printing quarterly revenue of $48.9 million ("mm"). The bolus of upside was driven by a 37% YoY gain in cardiovascular revenues, and 'other' revenues of 14%, offset by weakness in fluid delivery and ophthalmology, as seen in Exhibit 1. Meanwhile, COGS saw a 13% YoY gain due to the higher revenue volumes, whereas inventories lifted by ~690bps YoY. The spike in inventory value was driven by a 13% increase in raw material value, in-line with market trends and the commodity bull run of the past 12 months. This resulted in a gross profit of $20.8mm, up 16.6% YoY on a gross margin of 42.6%. Exhibit 1. The cardiovascular business continues to be the major performer on a sequential basis. Revenue split continues to shift toward a more even distribution towards cardiovascular. Cardiovascular margin is now ~37% of turnover in Q2 FY22. Note: Adapted from ATRI Q2 FY22 10-Q (Image: HB Insights. Data: ATRI) As seen in Exhibit 2, quarterly operating trends have been consistently buoyant for ATRI from FY15-date. Both turnover and operating profit have ticked up from low-points during the pandemic, whereas FCF [net of dividends] has been narrowing from FY20-date. We note the QoQ decline in FCF yield that investors have realized over this time, which, at face value looks to be quite alarming. Exhibit 2. Quarterly operating metrics demonstrate the resiliency on offer, with sales and pre-tax earnings both lifting back above pre-pandemic levels. Noted is the declining FCF yield on tighter FCF conversion, however, as we discuss below, this is coupled with favorable return on investment to justify the case. Note: [All earnings figures in $mm or %]. Quarterly operating measures are plotted against TTM FCF yield to observe effect of invested capital and return on invested capital. Calculations are made from GAAP earnings with no reconciliations. (Image: HB Insights; Data: ATRI SEC Filings) In light of the tightening FCF and FCF yields our findings illustrate that ATRI's return on investment has remained in the double digits across the examination period. Whilst FCF [net of dividends] has narrowed sequentially, ROIC has remained high and curled up since late FY21 on a TTM basis, as seen in Exhibit 3. This tells us the company is amid a strong capital budgeting cycle that has seen it invest more than it made during the period [in Q2 FY22 in particular]. The combination of negative FCF and rising return on investment is a favorable combination that is incredibly attractive in the current climate. Exhibit 3. Despite tightening FCF and realized FCF yields since FY15, ATRI continuously delivers double-digit return on investment that comfortably outpaces the WACC hurdle of 5% by ~2.8 turns. Note: All figures are in $mm or %. Invested capital is calculated with capitalized R&D investment from the income statement. (Image: HB Insights. Data: ATRI SEC filings) Valuation Shares are trading at 32x trailing earnings, ahead of the sector median's 26.6x. The stock is also priced at 4.5x book value, again a step above the sector's 2.2x. We need to understand what we're buying in ATRI. Valuation is a combination of investment, return on investment and earnings by our estimate - what's real, and what's expected.
분석 기사 • Aug 27

Atrion's (NASDAQ:ATRI) Upcoming Dividend Will Be Larger Than Last Year's

The board of Atrion Corporation ( NASDAQ:ATRI ) has announced that it will be paying its dividend of $2.15 on the 30th...
Seeking Alpha • Aug 22

Atrion raises dividend 10.3% to $2.15/share

Atrion (NASDAQ:ATRI) declares $2.15/share quarterly dividend, 10.3% increase from prior dividend of $1.95. Forward yield 1.38% Payable Sept. 30; for shareholders of record Sept. 15; ex-div Sept. 14. See ATRI Dividend Scorecard, Yield Chart, & Dividend Growth.
분석 기사 • Jul 18

Some Investors May Be Worried About Atrion's (NASDAQ:ATRI) Returns On Capital

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
분석 기사 • Jan 03

Atrion (NASDAQ:ATRI) Could Be Struggling To Allocate Capital

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
분석 기사 • Nov 18

Atrion's (NASDAQ:ATRI) Dividend Will Be Increased To US$1.95

Atrion Corporation ( NASDAQ:ATRI ) will increase its dividend on the 15th of December to US$1.95. This takes the annual...
분석 기사 • Sep 03

Atrion's (NASDAQ:ATRI) Dividend Will Be Increased To US$1.95

Atrion Corporation's ( NASDAQ:ATRI ) dividend will be increasing to US$1.95 on 30th of September. This takes the annual...

이 섹션에서는 일반적으로 전문 애널리스트들의 컨센서스 추정치를 기반으로 매출 및 이익 성장 전망을 제시하여 투자자들이 회사의 수익 창출 능력을 이해하도록 돕습니다. 그러나 Atrion는 과거 데이터가 충분하지 않고 애널리스트 예측도 없어, 과거 데이터를 단순히 외삽하거나 애널리스트 전망을 사용하여 향후 이익을 신뢰할 수 있게 계산할 수 없습니다.

Simply Wall St가 다루는 기업 중 97%는 과거 재무 데이터를 보유하고 있기 때문에, 이는 상당히 드문 상황입니다.

이익 및 매출 성장 예측

NasdaqGS:ATRI - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
6/30/2024182132839N/A
3/31/202417719927N/A
12/31/202316919-220N/A
9/30/202316921-199N/A
6/30/202317127-2114N/A
3/31/202317630-1221N/A
12/31/202218435-529N/A
9/30/202218135939N/A
6/30/2022179341741N/A
3/31/2022173342343N/A
12/31/2021165332339N/A
9/30/2021157322139N/A
6/30/2021148311536N/A
3/31/2021143311234N/A
12/31/2020148321739N/A
9/30/2020150331535N/A
6/30/2020155351838N/A
3/31/2020157362242N/A
12/31/2019155372242N/A
9/30/2019156362747N/A
6/30/2019156362746N/A
3/31/2019155352846N/A
12/31/2018152342643N/A
9/30/2018152352843N/A
6/30/2018150343648N/A
3/31/201814735N/A47N/A
12/31/201714737N/A47N/A
9/30/201714634N/A46N/A
6/30/201714633N/A43N/A
3/31/201714631N/A40N/A
12/31/201614328N/A37N/A
9/30/201614328N/A38N/A
6/30/201614228N/A38N/A
3/31/201614428N/A40N/A
12/31/201514629N/A40N/A
9/30/201514629N/A38N/A
6/30/201514529N/A34N/A
3/31/201514328N/A32N/A
12/31/201414128N/A31N/A
9/30/201414028N/A32N/A
6/30/201413728N/A35N/A
3/31/201413527N/A36N/A
12/31/201313227N/A37N/A
9/30/201312926N/A33N/A

애널리스트 향후 성장 전망

수입 대 저축률: ATRI 의 예상 수익 증가율이 절약률(2.5%)보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: ATRI 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: ATRI 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: ATRI 의 수익이 US 시장보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 매출: ATRI 의 수익이 연간 20%보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: ATRI의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2024/08/21 03:04
종가2024/08/21 00:00
수익2024/06/30
연간 수익2023/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Atrion Corporation는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Norbert KalliwodaDr. Kalliwoda Research